Callan JMB Inc. (NASDAQ: CJMB) has agreed to act as the independent third‑party overseer of Attune Biotech’s (d/b/a Biostax Corp.) manufacturing, quality assurance, and deployment operations for the investigational new drug JKB‑122, marketed as lodonal™. The agreement expands CJMB’s role from advisory to hands‑on oversight of the critical clinical‑trial supply chain for the drug’s Long COVID IND trials.
Under the terms, CJMB will qualify and validate the contract manufacturing organization, conduct comprehensive batch‑record reviews, verify the supply chain, assess surge‑manufacturing capacity, and validate distribution pathways. The partnership follows a strategic teaming agreement signed in January 2026 that broadened CJMB’s involvement in federal medical countermeasure programs.
JKB‑122 is a first‑in‑class TLR4 antagonist designed to restore immune homeostasis in patients with Long COVID, a condition affecting an estimated 20 million Americans and for which no FDA‑approved therapies exist. Attune Biotech’s pipeline also targets HIV immune non‑responders, autoimmune hepatitis, metabolic liver diseases, and chronic immune pain.
Wayne Williams, founder and CEO of Callan JMB, said the new role “represents a significant expansion of Callan JMB’s role in the federal medical countermeasure ecosystem.” Attune Biotech’s CEO, Noreen Griffin, highlighted the company’s focus on precision‑based therapeutics and an AI‑powered care platform, while an unnamed Attune representative noted that Callan’s federal relationships and operational framework make it uniquely suited to support the advancement of the development pipeline.
The collaboration positions CJMB as a key logistics partner for a biopharmaceutical company targeting an underserved patient population, potentially generating new revenue streams and enhancing the company’s profile in the life‑sciences supply‑chain market. The partnership also strengthens Attune’s ability to deliver a rigorously monitored supply chain for its lead program, supporting the company’s broader strategy to bring innovative immune‑modulating therapies to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.